P53 and RB: Simple interesting correlates or tumor markers of critical predictive nature?

被引：21

作者：

Cordon-Cardo, C ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 06期

关键词：

D O I：

10.1200/JCO.2004.12.994

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：975 / 977

页数：3

共 17 条

[1] Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma [J].

Chatterjee, SJ ;

Datar, R ;

Youssefzadeh, D ;

George, B ;

Goebell, PJ ;

Stein, JP ;

Young, LL ;

Shi, SR ;

Gee, C ;

Groshen, S ;

Skinner, DG ;

Cote, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1007-1013

[2] The INK4a/ARF tumor suppressor: one gene - two products - two pathways [J].

Chin, L ;

Pomerantz, J ;

DePinho, RA .

TRENDS IN BIOCHEMICAL SCIENCES, 1998, 23 (08) :291-296

[3]

CORDONCARDO C, 1995, AM J PATHOL, V147, P545

[4] ALTERED EXPRESSION OF THE RETINOBLASTOMA GENE-PRODUCT - PROGNOSTIC INDICATOR IN BLADDER-CANCER [J].

CORDONCARDO, C ;

WARTINGER, D ;

PETRYLAK, D ;

DALBAGNI, G ;

FAIR, WR ;

FUKS, Z ;

REUTER, VE .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1992, 84 (16) :1251-1256

[5]

CordonCardo C, 1997, CANCER RES, V57, P1217

[6]

ESRIG D, 1993, AM J PATHOL, V143, P1389

[7]

FUJIMOTO K, 1992, CANCER RES, V52, P1393

[8] Issues and barriers to development of clinically useful tumor markers: A development pathway proposal [J].

Hammond, MEH ;

Taube, SE .

SEMINARS IN ONCOLOGY, 2002, 29 (03) :213-221

[9] Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers [J].

Hayes, DF ;

Bast, RC ;

Desch, CE ;

Fritsche, H ;

Kemeny, NE ;

Jessup, JM ;

Locker, GY ;

MacDonald, JS ;

Mennel, RG ;

Norton, L ;

Ravdin, P ;

Taube, S ;

Winn, RJ .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (20) :1456-1466

[10]

Lu ML, 2002, CLIN CANCER RES, V8, P171

← 1 2 →